Tokyo Metropolitan Bokutoh Hospital (東京都立墨東病院) is located in Kotobashi, Sumida, Tokyo, Japan. It has 765 beds and is run by the Tokyo Metropolitan Government.
Nerve entrapment at the fracture site in pediatric supracondylar humerus fractures remains uncommon but may lead to permanent injury and suboptimal neurological recovery. This study presents three case reports of nerve entrapment at the fracture site, with or without vascular compromise, identified within a consecutive series of 150 pediatric supracondylar humerus fractures managed over a 10-year period. Nerve entrapment was diagnosed intraoperatively, followed by immediate release, fracture reduction, and fixation in the acute setting. All patients achieved complete neurological recovery after surgery and did not require delayed surgical intervention. Surgeons should recognize the possibility of nerve entrapment at the fracture site when closed reduction is unsuccessful, vascular compromise coexists, or perfusion status or nerve palsy worsens following attempts at closed reduction. Early nerve exploration and release in the acute setting may improve the likelihood of favorable neurological outcomes.
PURPOSE:Few reports have investigated the attitudes of medical students and early residents toward medical oncology and their career decisions. This study aimed to assess recognition, interest, and factors influencing the intention to specialize in medical oncology among medical students and junior residents. METHODS:A 20-item questionnaire survey was conducted online from November to December 2024. Participants were recruited from medical universities, university hospitals, and general hospitals across Japan. Responses regarding perceptions of medical oncology and decisive factors for career choice were analyzed. RESULTS:A total of 632 medical students and junior residents completed the survey. Among them, 545 (86%) recognized medical oncology, and 243 (38%) considered it a potential future career. The correlation coefficient between academic year and recognition of medical oncology was 0.976, whereas that between academic year and interest was -0.810. Sensitivity of interest, defined as the proportion of participants considering medical oncology as a career among those interested in it, was highest in third-year students (0.78). Multivariate analysis identified interest in cancer treatment as the strongest predictor of considering medical oncology as a career (contribution rate, 43%; range, 1.62; partial correlation coefficient, 0.28). CONCLUSION:Recognition of medical oncology increased with academic year, whereas interest declined. Interest in cancer treatment was the strongest predictor of intention to specialize in medical oncology.
BACKGROUND:This randomized controlled trial provided LC16m8 pre-exposure prophylaxis to high-risk individuals to assess its efficacy for mpox prevention, safety, and immunogenicity. METHODS:This multicenter, randomized, open-label trial enrolled men and women aged ≥18 years at high risk of mpox. Participants were randomly assigned 1:1 to early- or late-vaccination groups. The primary endpoint was vaccine efficacy (VE) against mpox. Secondary endpoints included VE against severe mpox, symptoms, "take" incidence, adverse events (AEs), and immunogenicity in participants with human immunodeficiency virus (HIV). RESULTS:In total, 570 and 565 participants were assigned to early- and late-vaccination groups, respectively, with 530 and 476 vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had HIV. No mpox cases occurred, precluding VE calculations. The take rates were 89.5% (with HIV) and 93.9% (without HIV). AEs occurred in 97.2% and 98.2% of participants with and without HIV, respectively. No fatal AEs were observed. Serious adverse events (SAEs) were observed in 2/352 (0.6%) and 3/654 (0.5%) of participants with and without HIV, respectively, of which 1 SAE causally related to vaccination occurred in a participant without HIV. Seroconversion rates for LC16m8 and MPXV were 96.2% and 69.2%, respectively, in participants with HIV, and 92.0% and 52.0%, respectively, in individuals without HIV. CONCLUSIONS:LC16m8 efficacy in mpox remains inconclusive. However, in individuals with well-controlled HIV, it was immunogenic and raised no significant safety concerns, suggesting its suitability for targeted vaccination of at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137).
BACKGROUND:In Japan, thawed plasma (TP) is not used because of the short expiration time of fresh frozen plasma (FFP) post-thawing. We developed and implemented a new massive transfusion protocol (MTP) using TP and expired TP and evaluated its impact on plasma waste, transfusion response times, and patient outcomes. STUDY DESIGN AND METHODS:Phase 1: From November 2023 to March 2024, we investigated the clinical use of TP and the expiration rate of TP derived from 480 mL of FFP (blood type: AB). The cryoprecipitate was prepared from expired TP (TP-CRYO), and its coagulation factors were measured. Phase 2: From April 2024 to March 2025, TP-CRYO was incorporated into a regular stock of type-AB cryoprecipitate and administered to patients with massive bleeding. Clinical data, fibrinogen levels, and adverse events were investigated in patients who received TP and in those who received cryoprecipitate, including TP-CRYO. RESULTS:During phase 1, TP was administered to 11 patients and 22 bags of TP expired. Compared with the conventionally prepared cryoprecipitate, TP-CRYO had slightly higher clotting activity and fibrinogen levels. During phase 2, TP was administered to 55 patients, using 42 bags of expired TP. One bag of TP-CRYO was discarded owing to early patient transfer, one due to fibrin formation, and three remained in stock. The other 37 were administered. The plasma waste rate decreased from 66.7% to 2.1%. No direct adverse events were associated with TP or TP-CRYO use. DISCUSSION:We established a sustainable MTP using TP and in-house cryoprecipitate from TP-CRYO.
BACKGROUND:Antimicrobial de-escalation (ADE) is recommended within antimicrobial stewardship programs; however, its safety and impact on multidrug-resistant organism (MDRO) emergence in critically ill patients remain uncertain. METHODS:We retrospectively studied adults (aged≥18 years) in a 12-bed intensive care unit (ICU) of a tertiary hospital in Tokyo, Japan, who received empirical antimicrobials for ≥72 h between January 2020 and December 2024. Patients were classified into ADE and No-ADE groups according to the European Society of Intensive Care Medicine/European Society of Clinical Microbiology and Infectious Diseases criteria. The primary outcome was 28-day mortality, whereas secondary outcomes were 90-day mortality and new MDRO detection. Multivariable and propensity score-matched analyses were performed. RESULTS:Among 960 patients, ADE occurred in 330 (34.4%). No significant differences were observed between ADE and No-ADE groups in 28-day mortality (11.8% vs. 10.8%) or 90-day mortality (17.3% vs. 17.5%). The proportion of patients with newly detected MDRO within 90 days was lower in the ADE group (5.5% vs. 9.2%). However, ADE was not independently associated with mortality. Although crude MDRO incidence was lower in the ADE group, multivariable analysis showed a statistically significant association between ADE and MDRO detection. ADE was associated with shorter empirical antimicrobial duration and ICU stay. CONCLUSIONS:ADE was not associated with increased mortality. Reduced empirical antimicrobial exposure and shorter ICU stay likely reflect stewardship-related processes rather than a direct causal effect.